Literature DB >> 19182484

Multisubstance use as a feature of addiction to anabolic-androgenic steroids.

Kurt Skarberg1, Fred Nyberg, Ingemar Engstrom.   

Abstract

The aim of this study was to explore and describe total drug use among anabolic-androgenic steroid (AAS) users and the reasons given for the use of these drugs. The study was based on semi-structured interviews and questionnaires involving 32 patients who were attending an addiction centre in Orebro, Sweden, for AAS use. The results indicated that a history of polysubstance use among the patients was frequent. Over half were using drugs of abuse and also taking various other pharmaceuticals. Almost half of the patients took human growth hormones, and almost half of the interviewed persons were drinking alcohol to a hazardous or harmful extent. The most common reason given for taking AAS and other hormones was to increase muscle mass and strength, but some participants also used insulin as a means of losing fat. Cannabis was used to improve sleep, heroin to decrease pain and amphetamine to increase endurance and burn fat. Our data suggest that most of the current AAS users who have been admitted to a treatment programme are multiple drug users with polysubstance dependence. The study stresses the importance of carefully examining total drug use as part of the assessment regimen for this group. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182484     DOI: 10.1159/000199045

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  30 in total

1.  Culture, psychosomatics and substance abuse: the example of body image drugs.

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Psychother Psychosom       Date:  2012-01-18       Impact factor: 17.659

2.  Risk factors for illicit anabolic-androgenic steroid use in male weightlifters: a cross-sectional cohort study.

Authors:  Harrison G Pope; Gen Kanayama; James I Hudson
Journal:  Biol Psychiatry       Date:  2011-08-12       Impact factor: 13.382

Review 3.  Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions.

Authors:  Eberhard Nieschlag; Elena Vorona
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

4.  Effectiveness of Anabolic Steroid Preventative Intervention among Gym Users: Applying Theory of Planned Behavior.

Authors:  Farzad Jalilian; Hamid Allahverdipour; Babak Moeini; Abbas Moghimbeigi
Journal:  Health Promot Perspect       Date:  2011-07-25

5.  Development and validation of the appearance and performance enhancing drug use schedule.

Authors:  Tom Hildebrandt; James W Langenbucher; Justine Karmin Lai; Katharine L Loeb; Eric Hollander
Journal:  Addict Behav       Date:  2011-05-11       Impact factor: 3.913

Review 6.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

Review 7.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

8.  Human growth hormone abuse in male weightlifters.

Authors:  Brian P Brennan; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Am J Addict       Date:  2010-11-12

Review 9.  Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications.

Authors:  Gen Kanayama; Kirk J Brower; Ruth I Wood; James I Hudson; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

10.  Cognitive deficits in long-term anabolic-androgenic steroid users.

Authors:  Gen Kanayama; Joseph Kean; James I Hudson; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.